Aspira Women’s Health Inc., a leading company in women’s health diagnostics, has announced an exciting development in its ongoing collaboration with BioReference Health, a subsidiary of OPKO Health. This expansion of their co-marketing and distribution agreement will see the OvaWatch® diagnostic tool included in BioReference’s growing portfolio of women’s health services. The move is designed to strengthen access to this innovative diagnostic solution across New York and New Jersey, where the companies hope to drive greater adoption without additional costs.
OvaWatch® is a cutting-edge, bio-analytical tool aimed at improving the early detection and diagnosis of gynecologic diseases, an area that remains a critical focus for Aspira Women’s Health. By combining advanced technology with sophisticated testing, OvaWatch® has the potential to significantly improve patient outcomes by helping healthcare providers in the region make more informed decisions.
Nicole Sandford, CEO of Aspira Women’s Health, expressed her enthusiasm for the expanded partnership, highlighting the shared mission of both organizations to improve women’s healthcare outcomes. “We are excited to deepen our collaboration with BioReference, a company that shares our commitment to advancing healthcare for women. This expansion provides a tremendous opportunity to accelerate the adoption of OvaWatch® across New York and New Jersey while ensuring we do so without incurring additional costs,” said Sandford.
The expansion of the collaboration will see BioReference incorporate OvaWatch® into its already extensive network of diagnostic offerings. The addition of this tool to BioReference’s portfolio is set to enhance the company’s capacity to support healthcare providers in the two states, improving the resources available to clinicians as they manage women’s health issues, particularly those relating to gynecologic diseases.
Ellen Beausang, Chief Commercial Officer of BioReference, also shared her excitement over the development, stressing the importance of adding OvaWatch® to the company’s roster of testing services. “The addition of OvaWatch® to our Women’s Health portfolio underscores BioReference Health’s commitment to offering top-tier testing that helps providers in New York and New Jersey better manage their patients and improve health outcomes,” Beausang said.
As part of the agreement, both companies are set to leverage each other’s strengths to ensure the smooth introduction and ongoing promotion of OvaWatch® in these key markets. The goal is clear: to bring the benefits of this advanced diagnostic tool to more women in the region, giving healthcare providers the means to detect and manage gynecologic conditions earlier and more effectively.
The new partnership also highlights a growing trend in healthcare towards collaboration between diagnostics companies and health providers. The industry seeks innovative solutions that can address the needs of women in an increasingly complex healthcare landscape. By working together, Aspira and BioReference aim to bring meaningful change to how women’s health is managed, focusing on early intervention and more accurate diagnostic pathways.
Aspira Women’s Health, with its focus on bio-analytical testing, has a proven track record in the development of diagnostic solutions for women’s health, while BioReference, as a major player in laboratory testing and diagnostics, brings its extensive distribution network to the table. Together, they are positioned to make a significant impact on the diagnosis and management of gynecologic diseases, a critical area that often requires better early detection tools.
This collaboration is poised to not only expand OvaWatch® ‘s reach but also to set a precedent for similar partnerships in the future, with the potential to bring further innovative healthcare solutions to the women who need them most.
As more women benefit from improved diagnostic services, the partnership between Aspira Women’s Health and BioReference could well become a model for how strategic alliances can drive healthcare improvements while maintaining cost efficiency.